Retrophin, LLC (RTRX) Initiates Global Access For RE-024 In Pantothenate Kinase-Associated Neurodegeneration (PKAN)
5/12/2014 8:55:09 AM
NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced that it has made RE-024 available to physicians who are treating critically ill patients with pantothenate kinase-associated neurodegeneration (PKAN) worldwide under local “compassionate use” regulations. RE-024 is a replacement therapy for phosphopantothenate, the reaction product and substrate that is missing in patients with PKAN.
Help employers find you! Check out all the jobs and post your resume.
comments powered by